Insights into endotoxin-mediated lung inflammation and future treatment strategies

Amlan Chakraborty, Jennifer C. Boer, Cordelia Selomulya, Magdalena Plebanski, Simon G. Royce

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Introduction: Airway inflammatory disorders are prevalent diseases in need of better management and new therapeutics. Immunotherapies offer a solution to the problem of corticosteroid resistance. Areas covered: The current review focuses on lipopolysaccharide (Gram-negative bacterial endotoxin)-mediated inflammation in the lung and the animal models used to study related diseases. Endotoxin-induced lung pathology is usually initiated by antigen presenting cells (APC). We will discuss different subsets of APC including lung dendritic cells and macrophages, and their role in responding to endotoxin and environmental challenges. Expert commentary: The pharmacotherapeutic considerations to combat airway inflammation should cost-effectively improve quality of life with sustainable and safe strategies. Selectively targeting APCs in the lung offer the potential for a promising new strategy for the better management and treatment of inflammatory lung disease.

Original languageEnglish
Pages (from-to)941-955
Number of pages15
JournalExpert Review of Respiratory Medicine
Volume12
Issue number11
DOIs
Publication statusPublished - 2 Nov 2018

Keywords

  • Airway inflammation
  • anti-inflammatories
  • antigen presenting cells
  • asthma
  • COPD
  • endotoxin

Cite this

Chakraborty, Amlan ; Boer, Jennifer C. ; Selomulya, Cordelia ; Plebanski, Magdalena ; Royce, Simon G. / Insights into endotoxin-mediated lung inflammation and future treatment strategies. In: Expert Review of Respiratory Medicine. 2018 ; Vol. 12, No. 11. pp. 941-955.
@article{fd3e7799d4054d9a8e9ef6176e020628,
title = "Insights into endotoxin-mediated lung inflammation and future treatment strategies",
abstract = "Introduction: Airway inflammatory disorders are prevalent diseases in need of better management and new therapeutics. Immunotherapies offer a solution to the problem of corticosteroid resistance. Areas covered: The current review focuses on lipopolysaccharide (Gram-negative bacterial endotoxin)-mediated inflammation in the lung and the animal models used to study related diseases. Endotoxin-induced lung pathology is usually initiated by antigen presenting cells (APC). We will discuss different subsets of APC including lung dendritic cells and macrophages, and their role in responding to endotoxin and environmental challenges. Expert commentary: The pharmacotherapeutic considerations to combat airway inflammation should cost-effectively improve quality of life with sustainable and safe strategies. Selectively targeting APCs in the lung offer the potential for a promising new strategy for the better management and treatment of inflammatory lung disease.",
keywords = "Airway inflammation, anti-inflammatories, antigen presenting cells, asthma, COPD, endotoxin",
author = "Amlan Chakraborty and Boer, {Jennifer C.} and Cordelia Selomulya and Magdalena Plebanski and Royce, {Simon G.}",
year = "2018",
month = "11",
day = "2",
doi = "10.1080/17476348.2018.1523009",
language = "English",
volume = "12",
pages = "941--955",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Taylor & Francis",
number = "11",

}

Insights into endotoxin-mediated lung inflammation and future treatment strategies. / Chakraborty, Amlan; Boer, Jennifer C.; Selomulya, Cordelia; Plebanski, Magdalena; Royce, Simon G.

In: Expert Review of Respiratory Medicine, Vol. 12, No. 11, 02.11.2018, p. 941-955.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Insights into endotoxin-mediated lung inflammation and future treatment strategies

AU - Chakraborty, Amlan

AU - Boer, Jennifer C.

AU - Selomulya, Cordelia

AU - Plebanski, Magdalena

AU - Royce, Simon G.

PY - 2018/11/2

Y1 - 2018/11/2

N2 - Introduction: Airway inflammatory disorders are prevalent diseases in need of better management and new therapeutics. Immunotherapies offer a solution to the problem of corticosteroid resistance. Areas covered: The current review focuses on lipopolysaccharide (Gram-negative bacterial endotoxin)-mediated inflammation in the lung and the animal models used to study related diseases. Endotoxin-induced lung pathology is usually initiated by antigen presenting cells (APC). We will discuss different subsets of APC including lung dendritic cells and macrophages, and their role in responding to endotoxin and environmental challenges. Expert commentary: The pharmacotherapeutic considerations to combat airway inflammation should cost-effectively improve quality of life with sustainable and safe strategies. Selectively targeting APCs in the lung offer the potential for a promising new strategy for the better management and treatment of inflammatory lung disease.

AB - Introduction: Airway inflammatory disorders are prevalent diseases in need of better management and new therapeutics. Immunotherapies offer a solution to the problem of corticosteroid resistance. Areas covered: The current review focuses on lipopolysaccharide (Gram-negative bacterial endotoxin)-mediated inflammation in the lung and the animal models used to study related diseases. Endotoxin-induced lung pathology is usually initiated by antigen presenting cells (APC). We will discuss different subsets of APC including lung dendritic cells and macrophages, and their role in responding to endotoxin and environmental challenges. Expert commentary: The pharmacotherapeutic considerations to combat airway inflammation should cost-effectively improve quality of life with sustainable and safe strategies. Selectively targeting APCs in the lung offer the potential for a promising new strategy for the better management and treatment of inflammatory lung disease.

KW - Airway inflammation

KW - anti-inflammatories

KW - antigen presenting cells

KW - asthma

KW - COPD

KW - endotoxin

UR - http://www.scopus.com/inward/record.url?scp=85054604729&partnerID=8YFLogxK

U2 - 10.1080/17476348.2018.1523009

DO - 10.1080/17476348.2018.1523009

M3 - Review Article

VL - 12

SP - 941

EP - 955

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 11

ER -